Merck wins FDA OK on 2nd round for ezetimibe/atorvastatin combo
This article was originally published in Scrip
Executive Summary
After being rejected by the US FDA last year, Merck managed to convince the agency on the second round to approve the company's ezetimibe-atorvastatin combo statin pill, which has been dubbed Liptruzet, as a treatment for primary or mixed hyperlipidemia.